Jin-Wei Liu

Jin-Wei Liu

Auto-generated profile, based on publicly available information

Jin-Wei Liu

Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
JLJin-Wei Liu
Jin-Wei Liu
YTYa-Wen Tsai
Ya-Wen Tsai
CLChih-Cheng Lai
Chih-Cheng Lai
HTHung-Jen Tang
Hung-Jen Tang
This study analyzed the epidemiological trends of three significant respiratory infectious diseases in Taiwan: invasive pneumococcal disease (IPD), influenza with severe complications, and tuberculosis during post-COVID-19 pandemic period. We utilized data from Taiwan's Centers for Disease Control and Prevention (CDC) website and classified the COVID-19 prevention policies into three phases for the year 2021, 2022, and 2023. We then performed a statistical analysis of reported case numbers for the three respiratory diseases during the 3-year period using the Kruskal-Wallis test, followed by joinpoint regression model for the identification of seasonal distribution and variation. An annual increase was observed in cases of IPD and influenza with severe complication, with influenza exhibiting a significant surge in 2023 (p < 0.001). IPD showed a non-significant upward trend (p = 0.111), while tuberculosis cases decreased annually (p = 0.114) with the gradual slowdown in the incidence rate reduction. Also, seasonal analysis revealed that IPD peaked in winter and spring, while influenza with severe complication peaked anomalously in the summer of 2023, suggestive of a prominent summer influenza. Finally, imported cases of influenza with severe complication, primarily from East and Southeast Asia, were noted only in 2023. The relaxation of COVID-19 preventive measures in Taiwan led to a marked resurgence of respiratory infectious diseases, particularly influenza with severe complication, accompanied by anomalous seasonality in 2023. This study highlights the need for continued vigilance and appropriate public health strategies, including vaccination and non-pharmaceutical interventions, to manage respiratory infectious diseases in the post-pandemic era.

17 November 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
JLJin-Wei Liu
Jin-Wei Liu
CLChih-Cheng Lai
Chih-Cheng Lai
CCChi-Chung Chen
Chi-Chung Chen
HCHsiu-Yin Chou
Hsiu-Yin Chou
CLCheng-Han Li
Cheng-Han Li
HCHung-Jui Chen
Hung-Jui Chen
With the introduction of novel antimicrobial agents, the threat posed by multidrug-resistant organisms has rapidly emerged. Among these, metallo-β-lactamase-producing carbapenem-resistant Enterobacterales (MBL-CRE) represent a significant challenge, severely limiting therapeutic options for clinicians. Our aim is to investigate the current burden and molecular epidemiology of carbapenemase-producing Enterobacterales (CPE) in Taiwan, with a particular focus on MBL producers. We conducted a multicenter, seven-year longitudinal study from 2018 to 2024, collecting carbapenem-resistant Enterobacterales isolates, and screening them for carbapenemase genes. A total of 1743 CPE isolates were included in this study. The most common species were Klebsiella pneumoniae (58.5 %), Escherichia coli (21.2 %), and Enterobacter cloacae complex (7.8 %), primarily recovered from urine and respiratory specimens. Among these isolates, 67.3 % harbored non-MBL genes and 32.7 % harbored MBL genes, with both types increasing significantly over time (both p < 0.001). In addition, a notable emergence of multiple-carbapenemase-producing Enterobacterales (M-CPE) was observed among various species, particularly K. pneumoniae, which exhibited the greatest diversity of carbapenemase gene combinations while E. coli co-harboring blaOXA-181 and blaNDM-5 accounted for the largest proportion of M-CPE isolates. Overall, the proportion of MBL producers among total CPE isolates increased from 22.3 % (95 % CI, 15.2-30.4 %) in 2018-40 % (95 % CI, 34.9-45 %) in 2024 with a statistical significance (p = 0.02). Among the six most frequently identified CPE species, K. pneumoniae and Citrobacter koseri were largely linked to non-MBL genes, while E. coli, Enterobacter cloacae complex, Citrobacter freundii, and Serratia marcescens were almost exclusively associated with MBL genes. The rising prevalence of MBL-CPE underscores the urgent need for strengthened infection control measures, ongoing genomic surveillance, and robust antimicrobial stewardship programs to prevent further emergence and transmission.

27 December 2024 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
CYCheng-Fa Yeh
Cheng-Fa Yeh
CCChi-Chung Chen
Chi-Chung Chen
CLChih-Cheng Lai
Chih-Cheng Lai
JLJin-Wei Liu
Jin-Wei Liu
HTHung-Jen Tang
Hung-Jen Tang
WSWen-Pin Su
Wen-Pin Su
Aeromonas infections pose a significant threat associated with high mortality rates. This study investigates the potential of mitomycin C (MMC), an anticancer drug, as a novel antimicrobial agent against Aeromonas infections. We evaluated the minimum inhibitory concentrations (MICs) of MMC and antibiotics against clinical Aeromonas isolates using broth microdilution. Synergistic effects of MMC with antibiotics were determined via time-kill studies. MMC's intracellular killing effects were analyzed using a representative Aeromonas isolate. Efficacy of combined therapies was assessed in a neutropenic mouse model. MMC-induced SOS response was evaluated using cell elongation method, and RNA extraction and quantitative real-time PCR. Combining 1/8⨯ MIC of mitomycin C (MMC) with either 1⨯ or 1/2⨯ MIC of LVX demonstrated significant synergistic effects over 24 h in vitro. In a neutropenic mouse model, the combination of MMC (2 mg/kg or 1 mg/kg) with LVX achieved survival rates of 100 % and 80 %, respectively, compared to 0 % survival with monotherapy. MMC induced marked cell elongation and division inhibition in response to escalating doses. However, the combination therapy's enhancement did not surpass the effects of individual drug treatments. Notably, combination therapy reduced recA activator levels below those observed with either drug alone, suggesting rapid bacterial cell death curtailed further expression of recA and lexA. Alternatively, extensive DNA damage may have overwhelmed bacterial DNA repair mechanisms, rendering them ineffective. These findings suggest that MMC may serve as a potential antimicrobial agent, particularly when used in combination with antibiotics. The integration of MMC with antibiotic therapy offers a promising approach for the treatment of Aeromonas infections and holds potential for future clinical applications.

27 July 2026 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
CYCheng-Fa Yeh
Cheng-Fa Yeh
CCChi-Chung Chen
Chi-Chung Chen
CLChih-Cheng Lai
Chih-Cheng Lai
PHPing‐Yu Hsu
Ping‐Yu Hsu
JLJin-Wei Liu
Jin-Wei Liu
WSWen-Pin Su
Wen-Pin Su